新闻中心

艾博兹医药与成都温江区政府达成战略协议，布局创新靶向放射性治疗药物研发及生产基地

2022-8-05

神领锐获得治疗神经痛全球首创新药在大中华区及新加坡的独家许可中国1900万糖尿病周围神经痛患者将迎来全新治疗药物

2022-7-21

Plexium Announces $102m Financing to Advance Pipeline of Targeted Protein Degradation Therapies and Technology Platform

2022-2-23

OncXerna is selected as Global Top 5 Precision Medicine Startups

2022-2-17

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

2022-1-10

鼎丰生科资本领投成立合资公司SanReno Therapeutics

2021-12-03

艾博兹医药完成7,500万美元的A轮融资，将为大中华市场的肿瘤患者带来创新靶向放射性治疗药物

2021-11-29

Zenas BioPharma从Xencor获得Obexelimab的全球独家权利

2021-11-23

极目生物合作伙伴Clearside Biomedical葡萄膜炎性黄斑水肿治疗药物XIPERE™（ARVN001）美国获批上市

2021-10-26

极目生物获得国内首项老视药物疗法ARVN003三期临床试验申请批准

2021-9-03

极目生物脉络膜上腔注射疗法ARVN001获东盟十国及印度独家权益

2021-8-15

QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements

2021-8-09

Engrail Therapeutics Extends Series A Financing to $64 Million

2021-8-03

极目生物低浓度阿托品儿童近视疗法ARVN002三期临床试验申请获批，创新微量给药技术助力近视防控

2021-8-02

神领锐医药宣布获得Neurolief公司的Relivion®在大中华区和韩国开发及商业化的独家许可协议

2021-7-09

Exscientia announces investment of up to $525M

2021-4-26

Evommune完成1250万美元种子轮融资

2020-11-20

Oncologie（鼎航医药）公布最新临床研究数据

2020-9-21

Arctic Vision Announces US$32MN in Series A

2020-7-14

Oncologie Launches with 16.5M USD Seed Funding Led by Pivotal bioVenture Partners China

2018-6-07

Pivotal bioVenture Partners China Closes Inaugural $150 Million Early Stage VC Fund

2018-5-24